This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
PER® designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-9999-16-083-H01-P. The activity is available for CE credit through June 27, 2017.
Instructions for Completing the Activity and Receiving Continuing Pharmacy Education (CPE) Credit
To receive CPE credit, pharmacist participants must log onto www.pharmacytimes.org where you will be directed to the activity pre-test. Participants must complete the pretest, read the article in its entirety, and complete the online evaluation and posttest with a score of 70% or better before the activity expires. After successful completion and submission of the online posttest and activity evaluation, your credit will be uploaded to CPE Monitor™. You may view your credit within 48 hours at www.mycpemonitor.net.
NOTE: All steps must be completed in order to receive credit. Please ensure that your Pharmacy Times account is updated with your NABP e-profile number and your date of birth (MMDD format). Participation data will not be uploaded into CPE Monitor™ if you do not have your NABP e-profile number and date of birth entered into your profile on www.pharmacytimes.org.
This activity will use the PER® Oncology Consultations® format, a series of four consultations between a medical oncologist and a pharmacist, including lively discussions around guideline-consistent care, novel therapeutic agents, barriers to effective management, and the role of the multi-disciplinary team in patient center care, in an effort to improve patient outcomes. The discussions will also place relevant information presented at recent society meetings into clinical context.
Instructions For This Activity & Receiving Credit
This educational initiative is directed toward physicians and clinical pharmacists including those in specialty, hospital-based and health-system pharmacy settings, involved in the care of patients who currently receive cancer therapy and are at risk for or encountering CINV. Other health care professionals with an interest in managing CINV will also be invited to participate.
Richard Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York
Disclosure: Consultant: Merck, Tesaro, Helsinn, Eisai; Other Support: Honoraria: Merck, Helsinn, Eisai
Sally Yowell Barbour, PharmD, BCOP, CPP
Director of Oncology Pharmacy Programs
PGY2 Oncology Residency Director
Clinical Pharmacist Practitioner
Department of Pharmacy
Duke Uinversity Hospital
Durham, North Carolina
Disclosure: Other Support: Travel support for presentation: Tesaro.
The planning staff of PER® and PTCE™ (Dave Heckard; Mary Jo Dixon, RPh; PharmD, RPh; Donna Fausak).
It is the policy of Physicians' Education Resource®, LCC (PER®), and Pharmacy Times Continuing Education™ (PTCE™) to ensure the fair balance, independence, objectivity, and scientific rigor in all of our CME/CPE activities. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE) guidelines, PER® and PTCE™ require everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® and PTCE™ have implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CPE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CPE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, and/or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® and PTCE™, or the company that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY